Myocardial infarction: When and how should we initiate treatment with ACE inhibitors?

Roberto Latini, Aldo P. Maggioni, Giulio Zuanetti

Research output: Contribution to journalArticlepeer-review


Recent trials have shown that angiotensin-converting enzyme (ACE) inhibitors can reduce mortality and the occurrence of severe left ventricular dysfunction (LVD) when started within the first day after acute myocardial infarction and continued for 4-6 weeks thereafter. When started within this time window, ACE inhibitors are safe in relatively unselected myocardial infarction (MI) patients provided they are clinically and hemodynamically stable. GISSI-3, ISIS-4 and CCS-1 studies show that more than half of the lives are saved by ACE inhibitor treatment within the first week of therapy. Although the benefit from ACE inhibitors is larger in patients presenting with congestive heart failure (Killip class > 1), the number of lives saved in patients at low risk, who represent the majority of the population, is relevant. This supports the approach of treating all hemodynamically stable MI patients. Treatment could be stopped after about 1 month in patients without evidence of LVD while those with LVD should follow a long-term therapy with ACE inhibitors.

Original languageEnglish
Pages (from-to)16-22
Number of pages7
Issue numberSUPPL. 1
Publication statusPublished - Dec 1995


  • Angiotensin-converting enzyme
  • Clinical trials
  • Myocardial infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Myocardial infarction: When and how should we initiate treatment with ACE inhibitors?'. Together they form a unique fingerprint.

Cite this